Yipin Hong (300723.SZ) subsidiary's innovative drug APH03621 tablet has been accepted for clinical trial registration application.

Zhitrust Financial APP News, Yipin Hong (300723.SZ) issued an announcement. Recently, the drug clinical trial application for APH03621 tablets, an innovative drug independently developed by the company's wholly-owned subsidiary Guangzhou Yipin Hong Pharmaceutical Co., Ltd., has been accepted by the National Medical Products Administration, and received the "Acceptance Notice".